Genetic modulation of fetal hemoglobin in hydroxyureatreated sickle cell anemia To the Editor:
HbF levels are associated with haplotypes of the HBB gene cluster although the mechanisms accounting for this are largely unknown.
Genome-wide association studies (GWAS) have revealed three quantitative trait loci (QTL), HBG2 on chromosome 11p15, HBS1L-MYB (HMIP) intergenic region on chromosome 6q23 and BCL11A on chromosome 2p16, which account for 20%-50% of HbF variation in sickle cell anemia (SCA). The olfactory receptors genes might have a regulatory role in g-globin gene expression. 1, 2 Hydroxyurea (HU) induces the production of HbF in SCA, providing a pharmacological therapeutic approach for ameliorating clinical complications. 3 Accordingly, we analyzed HBB haplotypes along with York, NY) and P values <.05 were considered significant.
Hematologic data from patients taking and not taking HU are shown in Table 1 . The dose of HU was available in all HU treated patients; mean length of use was 13.4 6 9.7 months (median 12 months; 2-50 months). Fifteen mg/kg/day was used in 47.6% of cases, followed by 26.2% using 25 mg/kg/day and 23.8% using 20 mg/kg/ day; 1 patient received the maximum tolerated dose of 35 mg/kg/day and was excluded from the analysis. The dose of 25 mg/kg/day was associated with lower platelet count (P 5 .03) and mean platelet volume (MPV) (P 5 .08) (Supporting Information Table 1 ). Exposure to HU for more than 12 months was associated with lower reticulocyte counts (P 5 .03) and higher direct bilirubin level (P 5 .02). There was no correlation between HU dose and HbF response, as described previously. 4 This might be consequence of individualized pharmacodynamics and metabolism of HU. SNP genotypes in BCL11A (rs766432, rs6732518), HBS1L-MYB (rs11759553, rs35959442) and OR51B5/6 (rs4910755, rs7483122) were successfully assayed in 141 patients and are shown in Supporting Information Table 2 . In patients on HU there was a significant association with homozygosity for the minor allele (C) of rs766432 in BCL11A with an increased hemoglobin concentration (P 5 .03), RBC count (P 5 .01), and hematocrit (P 5 .02). This same group had lower platelet count (P 5 .05) and direct bilirubin (P 5 .04) (Supporting Information RBC, red blood cell; MCV, mean cell volume; LDH, lactate dehydrogenase; WBC, white blood cell. P-value obtained using Mann-Whitney and *P-value using t test. Bold values indicate significance at P < .05 between patients not using and using HU.
suggest that SCA patients homozygous for the minor allele of BCL11A rs766432 and who use HU had greater increases in HbF expression and corresponding improvement in hematological parameters.
The results of a study with polymorphisms in BCL11A and OR51B5/6, and HBS1L-MYB in 622 Brazilian sickle cell disease patients including patients with HbSC disease and SCA who were not taking HU were similar to the present study. 5 
